Title : Discrimination between tumour and normal cells by staining with 3,4,5,6,16,17-hexadehydro-16-(methoxycarbonyl)-19 alpha-methyl-20 alpha-oxayohimbanium: the uracil ring as a target for the specific interaction between RNA(s) and the fluorescent probe - Salmon_1996_Anticancer.Res_16_1881 |
Author(s) : Salmon JM , Yassine M , Vo-Dinh T , Isola NR , Rebillard X , Viallet P |
Ref : Anticancer Research , 16 :1881 , 1996 |
Abstract :
3,4,5,6,16,17-Hexadehydro-16-(methoxycarbonyl)-19 alpha-methyl-20 alpha-oxayohimbanium (Alstonine) is a fluorescent alcaloid which has been known to stain tumour cells more efficiently than normal ones. In this paper the spectral properties of Alstonine were first investigated and its capability for preferential staining of tumour cells verified in culture using SK-OV-3 cells as tumour cells and Mouse 3T3 fibroblasts as controls. Then interactions between Alstonine and biological macromolecules were investigated to provide the rationale for preferential labelling. Molecular filtration techniques have demonstrated that binding occurs only with RNA molecules. Similar experiments were performed with different isopolynucleotides to find an explanation for that specificity. They provide evidence that binding occurs only in the presence of a uridyl ring. This is consistent with the specificity of the linkage to RNA. As the linkage of Alstonine with RNA did not induce any shift or obvious change in the intensity of its fluorescence spectrum, it is concluded that the binding might involve the side chain of the fluorescent compound. |
PubMedSearch : Salmon_1996_Anticancer.Res_16_1881 |
PubMedID: 8712716 |
Salmon JM, Yassine M, Vo-Dinh T, Isola NR, Rebillard X, Viallet P (1996)
Discrimination between tumour and normal cells by staining with 3,4,5,6,16,17-hexadehydro-16-(methoxycarbonyl)-19 alpha-methyl-20 alpha-oxayohimbanium: the uracil ring as a target for the specific interaction between RNA(s) and the fluorescent probe
Anticancer Research
16 :1881
Salmon JM, Yassine M, Vo-Dinh T, Isola NR, Rebillard X, Viallet P (1996)
Anticancer Research
16 :1881